FIGURE 1.

Drugs used in the treatment of IgAN via regulation of the inflammation-related signaling pathways. There are several inflammation-related pathways involved in the renal inflammation of IgAN, which can be used as pharmacological targets. The NLRP3 inflammasome plays a vital role among these pathways and can be activated by triggering activation of the NF-κB. Some drugs such as SchB, AH, LCC18 can act directly on the NLRP3 inflammasome or its upstream regulatory signaling, thus suppressing the proinflammatory pathways, decreasing the expression of inflammatory cytokines, and attenuating infiltration by inflammatory cells. These effects improve the renal pathology and kidney function in IgAN. Additionally, drugs such as LCC18, and resveratrol can also enhance autophagy, thereby inhibiting the NLRP3 inflammasome. Therefore, these drugs can exert a renoprotective effect in IgAN.